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In the last few decades, our understanding of Langerhans cells (LCs) has drastically 
changed based on novel findings regarding the developmental origin and biological func-
tions of these epidermis-specific resident immune cells. It has become clear that LCs 
not only exert pivotal roles in immune surveillance and homeostasis but also impact on 
pathology by either inducing tolerance or mediating inflammation. Their unique capabil-
ities to self-renew within the epidermis, while also being able to migrate to lymph nodes 
in order to present antigen, place LCs in a key position to sample the local environment 
and decide on the appropriate cutaneous immune response. Exciting new data distin-
guishing LCs from Langerin+ dermal dendritic cells (DCs) on a functional and ontogenic 
level reveal crucial roles for LCs in trauma and various skin pathologies, which will be 
thoroughly discussed here. However, despite rapid progress in the field, the exact role of 
LCs during immune responses has not been completely elucidated. This review focuses 
on what mouse models that have been developed in order to enable the study of murine 
LCs and other Langerin-expressing DCs have taught us about LC development and 
function.
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iNTRODUCTiON
Paul Langerhans first described Langerhans cells (LCs) in 1868. These cells were identified in the 
epidermis and reminiscent of neurons due to their dendritic morphology. Over a century later, 
Ralph Steinman discovered antigen presentation by dendritic cells (DCs) (1). LCs were subsequently 
classified as DCs (2) that are localized in the outermost layer of the skin, namely the epidermis, 
where they reside in close association with keratinocytes, the main epidermal cell type. LCs are 
also present in other stratified epithelia, such as the mucosal oral and vaginal epithelium. Recent 
studies show that these mucosal LCs functionally act as genuine LCs, although they originate from 
different precursors (3). In this review, we uniquely focus on LCs present in the skin epithelium. 
Keratinocytes undergo a specialized form of cell death, resulting in the formation of the cornified 
layers of the skin that are crucial in the establishment of a tight epidermal permeability barrier. 
Establishing a proper skin barrier is a prerequisite for terrestrial life, as it protects the body from 
dehydration and invasion of pathogens. Besides structural cells such as keratinocytes, the epidermis 
harbors different immune cell types, namely LCs, tissue-resident T-cells, and γδ T-cells (dendritic 
epidermal T cells; only in mice) that constitute the immunological skin barrier. Both keratinocytes 
and immune cells are essential for sensing the environment and function as a first line of defense 
against external insults (4). As such, LCs have proven crucial in various antimicrobial responses, 
which is reviewed in detail by West et al. in this research topic (5). For long, LCs were considered 
as the exclusive antigen presenting cells in the skin and a body of literature attributed a role to LCs 
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in the pathogenesis of various skin diseases. However, other DC 
subtypes reside in the dermis and a plethora of recent evidence 
challenged the paradigm that centers LCs as the sole cell type 
responsible for T-cell priming to antigens in the skin. LCs differ 
ontogenically from dermal DCs, as LCs share a common precur-
sor with macrophages, while dermal DCs are more closely related 
to conventional DC (cDC) subsets present in lymphoid tissues 
(6). Functionally, there appears to be a high level of redundancy 
between LCs and dermal DCs, whose specific phenotypes and 
functions are reviewed elsewhere (7, 8). LCs are able to migrate 
to the skin-draining lymph node, which is required for classi-
cal T-cell priming. LCs have recently been implicated in local 
immunosuppressive cutaneous reactions and activation of skin-
resident memory T-cells, indicating an important role for LCs in 
mediating the adaptive phase of skin immunity (9, 10).
Additionally, unlike cDCs, LCs have an embryonic origin 
and are largely maintained by self-renewal. In the past few years, 
there has been a lot of debate about the classification of LCs. 
Using developmental origin as a categorizing factor, which is 
encouraged in the complex field of the mononuclear phagocyte 
system (11), it is reasonable to classify LCs in the macrophage 
lineage. Expression of the transcription factor Zbtb46 enforces 
cDC identity (12). Recently, a highly elegant lineage tracing study 
corroborated the dual identity of LCs as these authors show that 
LCs express Zbtb46, while they originate from a Mafb-expressing 
progenitor, indicating macrophage origin (6). MafB was shown 
to control a network of self-renewal genes in proliferating resi-
dent macrophages (13). Like tissue-resident macrophages, LCs 
proliferate in a differentiated state, and these findings imply that 
MafB is likely involved in the proliferation of LCs. However, 
the specific molecular signals driving in  situ LC proliferation 
remain to be elucidated. These findings nicely summarize the 
current persuasion of LCs being macrophages with DC functions. 
Phenotypically, LCs share many features with cDCs, whereas 
their ontology relates them to tissue-resident macrophages. 
Together, this shows that LCs represent a highly unique cell type, 
sharing features with DCs but arising from a different origin and 
exerting unique functions that distinguish them from cDCs, as 
summarized in Figure 1.
PHeNOTYPe AND ONTOGeNY
Langerhans cells make up 3–5% of all nucleated cells in the epi-
dermis and occupy the stratum spinosum, a suprabasal epidermal 
layer that is characterized by “spiny” keratinocytes that undergo 
reinforcement of their cytoskeleton. LCs are stellate cells that 
protrude their dendrites via tight junctions toward the stratum 
corneum and as such can probe for antigens across several layers 
of the epidermis without disrupting the permeability barrier. 
LCs acquire a typical DC phenotype after birth by expressing 
major histocompatibility complex II (MHCII) molecules and 
the integrin αX chain (CD11c). Unlike mouse LCs, human LCs 
express low levels of CD11c and no F4/80, whereas they express 
CD1a and CD1c, two MHCI-related molecules involved in 
the presentation of lipid antigens (7). Epithelial cell adhesion 
molecule (EpCAM) regulates LC adhesion to keratinocytes and 
promotes LC migration to the draining lymph nodes (14). LCs 
express the C-type lectin Langerin (CD207), which is involved 
in the formation of Birbeck granules, endosomal organelles that 
are typical for LCs. These Birbeck granules have been shown to 
internalize viruses (15) and are thought to be part of the endo-
somal recycling complex (16). The presence of Langerin alone is 
not reliable to unambiguously define LCs, as Langerin expres-
sion has also been demonstrated on cDCs in the dermis, lungs, 
and spleen. Likewise, human and mouse LCs express SIRPα 
(CD172α), CD11b and CX3CR1, which is also expressed by 
most type 2 cDCs. Since the aforementioned markers are shared 
by different subsets of myeloid cells, multicolor flow cytometry 
with a minimal set of lineage imprinted markers is required for 
unequivocal identification of LCs in the skin and skin-draining 
lymph nodes (17).
Langerhans cells clearly share similarities with both DCs and 
macrophages (Figure 1). Doebel et al. recently summarized the 
emerging evidence of the dual identity of LCs, as they arise from 
macrophage precursors and acquire the unique properties of 
DCs in the epidermis (18). Indeed, LCs are radio-resistant cells 
from embryonic origin, which are maintained by self-renewal. 
With an estimated half-life of 2 months (19), LCs exhibit a slow 
proliferation rate in homeostatic conditions to replace dying 
and emigrating cells. In that aspect, LCs rather resemble tissue-
resident macrophages than classical DCs, which are derived from 
bone-marrow precursors and depend on circulating progenitors 
to retain their high turnover rate (18, 20). Unlike cDC precur-
sors that require FMS-like tyrosine kinase-3 (Flt3) signaling to 
differentiate, LCs develop independently of Flt3 and Fltl3 ligand 
(Flt3L). Of note, migrating LCs upregulate Flt3 expression, sug-
gesting a function of Flt3L in the activation of LCs (21). Like 
tissue-resident macrophages, LCs proliferate in a differentiated 
state and therefore express a set of self-renewal genes. However, 
the specific molecular signals driving in  situ LC proliferation 
remain to be elucidated.
Even though LCs share ontogenic similarities with tissue-resi-
dent macrophages, they are, unlike macrophages, able to migrate 
to draining lymph nodes. LCs can take up and process foreign 
antigens in steady-state conditions and inflammation, which they 
can present to cells of the adaptive immune system in the lymph 
nodes. The migration of LCs is a multistep process involving a 
plethora of changes. First, LCs need to weaken their intercellular 
connections with the surrounding keratinocytes, which is partly 
regulated by E-cadherin (2). The release of E-cadherin provokes 
translocation of β-catenin, which is involved in the tolerogenic 
phenotype of DCs (22). Canonical Wnt signaling, which is medi-
ated by β-catenin, is a master regulator of keratinocyte behavior 
in skin homeostasis and disease (23). It would, therefore, be 
interesting to investigate LC behavior in mouse models of aber-
rant cutaneous β-catenin activation in order to assess the involve-
ment of LCs in altering keratinocyte behavior. In a next step, LCs 
need to cross the basement membrane in order to migrate into 
the dermis to transit to the lymph node. Therefore, they locally 
secrete collagen-degrading matrix metalloproteinases, enabling 
dermal rearrangements and transdermal LC motility (24). Once 
in the dermis, LCs can enter the lymphatics in order to travel to 
regional lymph nodes. Reseeding of LCs from the bone marrow 
into the epidermis occurs through strictly mediated routes along 
FiGURe 1 | Schematic representation of the properties of Langerhans cell (LC) shared by dendritic cells (DCs) or macrophages. LCs display a mixture of properties, 
which they share with macrophages (indicated in green), such as self-maintenance and ontogeny. However, LCs are capable of presenting antigen and actively 
migrate to the draining lymph nodes, which qualifies them as DCs (properties shared between LCs and DCs are indicated in red).
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the hair follicle. Keratinocytes present in the region above the 
hair bulge secrete chemokine (C–C motif) ligand (CCL)-2 and 
CCL-20 (25).
A growth factor crucial for proper regulation of LC biology 
has proven to be transforming growth factor (TGF)-β and its 
associated transcription factors PU.1, Id2, and RUNX3. Mice 
deficient for one of these proteins lack fully developed LCs 
(26–28). TGF-β also drives differentiation of human precursor 
cells to cells with LCs characteristics in  vitro (29, 30). TGF-β 
signaling can be induced both by keratinocytes and LCs. 
However, the finding that mice with a conditional deletion of 
TGF-β in LCs exhibits reduced LC numbers is indicative for 
a crucial autocrine loop for TGF-β in LC biology (31). PU.1 
plays a pivotal role during many aspects of early hematopoiesis 
and myeloid cell differentiation and regulates the expression 
of the essential LC gene Runx3 in response to TGF-β (32). 
Interestingly, LCs under steady-state and inflammatory condi-
tions exhibit differential requirements for the TGF-β-induced 
transcription factor ID2, supporting the finding that inflamma-
tory LCs arise from different precursors than their steady-state 
counterparts (32, 33). The late endosomal adaptor molecule p14 
(LAMTOR2) is also indispensable for LC homeostasis and this 
appeared to be due to changes in TGF-β sensitivity (34, 35). 
Interestingly, p14-deficient LCs exhibit an increased sensitivity 
to apoptotic stimuli and defective proliferation, partially due 
to downregulation of the TGF-β receptor II. Another member 
of the TGF-β family shown to be important for the early steps 
of LC differentiation is bone morphogenetic protein (BMP) 7. 
Mice lacking BMP7 have significantly reduced LC numbers, 
and LCs appear less dendritic than in control littermates (36). 
These authors showed that the development of human LC could 
be driven by BMP7 in the case of redundant TGF-β signaling, 
as is the case in prenatal epidermis and in the basal epidermal 
layer (36). In conclusion, the number of LCs in the epidermis 
in homeostatic conditions is maintained by self-renewal that 
replenishes the constant low-level migration from the epidermis 
to the draining lymph nodes. The development, differentiation, 
and proliferation of LCs are tightly controlled by a network of 
transcription factors, cytokines, and growth factors, which are 
highly influenced by the tissue microenvironment.
LCs iN CUTANeOUS iNFLAMMATiON  
AND wOUND HeALiNG
Langerhans cells are, due to their location within stratified 
epithelia, part of the first line of defense to pathogens present in 
the environment. Non-activated LCs are constantly migrating to 
the lymph nodes to present self-antigen and establish immune 
tolerance in homeostatic conditions (37, 38). During pathogenic 
encounter, germ line-encoded pathogen-recognition receptors 
(PRRs) recognize molecular patterns on microbes, resulting in 
the secretion of pro-inflammatory cytokines and subsequent 
enhanced mobilization of LCs to the lymph nodes (39). The 
functional importance of LCs in infection and their interaction 
with PRRs is extensively reviewed by West et al. in this research 
topic (5).
Cutaneous inflammation, infection, or injury provokes exten-
sive migration of LCs from the epidermis, generating an empty 
niche that is repopulated by an initial wave of short-lived LCs 
arising from circulating Gr-1hi monocytes (33, 40). Seré et  al. 
reported that these monocyte-derived LCs that infiltrate the skin 
during inflammation are short-lived and independent of Id2, but 
their recruitment into the skin depends on CCR-2 and -6 (33). 
These short-lived LCs are gradually replaced by a second wave 
of Id2-expressing LCs that remain long-term in the epidermis 
and express high levels of Langerin, CD24, and EpCAM, which 
distinguishes them from short-lived LCs (33). These observations 
indicate the importance of distinct mechanisms for LC develop-
ment in homeostatic versus inflammatory conditions. LCs are 
imprinted by the epidermis as they require keratinocyte-derived 
interleukin (IL)-34 for their development, homeostasis, and 
regeneration (41).
Wound healing responses in the skin involve multiple cellular 
rearrangements to ensure rapid restoration of epidermal perme-
ability barrier function. Regenerative cutaneous responses can 
be subdivided into multiple phases, namely the inflammatory, 
new tissue formation, and tissue remodeling stage that are each 
characterized by specific molecular and cellular responses (42). 
Keratinocytes that are stressed during wounding rapidly upregu-
late ligands for the lymphocyte activation receptor natural killer 
group 2D (NKG2D), resulting in migration of LC populations 
out of the epidermis, followed by the appearance of αβ T-cells 
in the epidermis (43). Enhanced expression levels of the murine 
NKG2D ligand Rae-1ε have been observed in wounded skin, 
and mice lacking NKG2D exhibit delayed cutaneous wound 
healing (44), corroborating the importance of the cross talk 
between keratinocytes and LCs during regenerative processes 
in the skin. This intercellular interplay is already apparent in 
response to minor injury, such as repetitive tape-stripping of the 
epidermis (45). In these inflammatory conditions, LCs have been 
shown to penetrate the tight junctions that link keratinocytes, 
enabling endocytosis of antigens (46). LC–keratinocyte cross 
talk is in part established by the production of pro-inflammatory 
cytokines, such as IL-1, granulocyte macrophage colony stimulat-
ing factor (GM-CSF), and tumor necrosis factor (TNF), which 
are stimulators of LC migration (47). Hitherto, it is not known 
whether those cytokines can directly alter LC behavior in  vivo 
or whether this occurs indirectly via keratinocyte activation. 
Repopulation of the epidermis by LCs occurs in the final stages 
of wound healing, namely the tissue-remodeling stage (48). It 
remains unclear whether LC repopulation after wounding occurs 
through substantial infiltration of monocyte-derived LCs or 
through an initial wave of a small population of infiltrating LCs 
cells that proliferate in situ. In vitro data using primary human 
dermal lymphatic endothelial cells show that stimulation with 
TNF results in overexpression of key surface adhesion molecules 
(49). In human non-ulcerated epidermis from diabetic patients, 
which have markedly delayed cutaneous reparative responses, an 
increase in LCs was observed relative to normoglycemic patients. 
Higher numbers of LCs present in diabetic foot ulcers were 
associated with a better healing outcome, pointing to a beneficial 
role for human LCs in cutaneous reparative inflammation (50). 
In contrast, the observation that injury repair of the skin occurs 
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normally in mice lacking the PU.1 transcription factor, which is 
crucial for LC development (32), would argue for a redundant 
role of LCs in cutaneous regenerative responses (51). Clearly, 
the role of LCs in mediating the different stages of wound regen-
eration is still under debate, and it remains to be investigated 
whether targeting this cell population would be an interesting 
therapeutic avenue in managing wound-induced acute or chronic 
inflammation.
LCs iN ALLeRGiC SKiN ReACTiONS
Langerhans cells have been widely studied in allergic skin reac-
tions. However, the role of LCs in contact hypersensitivity and 
allergic sensitization remains controversial.
Contact Hypersensitivity
Allergic contact dermatitis occurs in individuals that mount a 
type IV delayed-type hypersensitivity against contact allergens, 
mostly small organic molecules with chemical reactivity (so-
called chemical sensitizers such as metals, topical antibiotics, or 
preservatives). These chemical sensitizers penetrate the cornified 
skin layers due to their small size and covalently bind to epider-
mal proteins to form the so-called “neo-antigens” that can be 
recognized by APCs (52). This process of haptenization can be 
bypassed experimentally by applying haptens to murine skin. The 
subsequent tissue responses mimic those arising during allergic 
contact dermatitis in humans. LCs are one of the first APCs to 
encounter these haptens but their exact role in CHS remains 
unclear due to conflicting results obtained from different mouse 
models, which is extensively reviewed elsewhere (53).
Initial reports demonstrated that depletion of LCs could not 
completely abrogate CHS responses to haptens (54, 55). This 
emphasized the redundancy of different DC subsets in the epi-
dermis and dermis, since dermal DCs can also be activated by 
haptens as these are small enough to penetrate into the dermis. 
Studies aiming to unravel the role of LCs in CHS made use of dif-
ferent mouse models to delete functional LCs, which resulted in 
contradictory findings. Genetic ablation of LCs can be achieved 
by injecting diphtheria toxin in mice expressing the human or 
simian diphtheria toxin receptor (DTR) driven by the CD207 
(Langerin) promoter. This toxin blocks protein translation and 
induces cell death only in cells that transgenically express DTR, 
as the mouse ortholog of this receptor is significantly less sensi-
tive to the toxin (56). In the skin of Langerin-DTR mice, all LCs 
and Langerin+ cDC1s can be depleted by a single injection of 
DT. By using this transgenic system, two reports showed that 
LCs were largely dispensable for the induction of CHS (54, 55). 
However, the notion that dermal Langerin+ cDC1s are also 
depleted in these mice calls for reconsideration of previous 
findings. In order to specifically investigate the contribution of 
LCs in CHS, CHS responses can be assessed 1 week after DT 
injection, since Langerin+ cDC1s are replenished from circulat-
ing precursors within 7 days, whereas LCs remain absent from 
the epidermis for at least 2  weeks. T-cell priming to topically 
applied haptens was diminished once Langerin+ cDC1s were 
reconstituted, while LCs were still depleted, indicating a role 
for LCs in CHS sensitization (57). Nevertheless, a functional 
redundancy exists between LCs and Langerin+ cDC1s, depend-
ing on the hapten dose (58).
An alternative method to assess the importance of LCs in CHS 
responses is to make use of human (h) Langerin-DTR mice, which 
constitutively lack LCs in the presence of functional Langerin+ 
cDC1s due to a different promoter regulation of the human CD207 
gene. Surprisingly, these mice showed an enhanced cutaneous 
sensitization to haptens, suggesting a suppressive role of LCs 
in CHS (59). However, these conclusions were refuted by other 
reports demonstrating that CHS responses were reduced in mice 
that only lack LCs due to conditional deletion of TGFβ receptor 
1 or p14 in the Langerin+ cells (35, 60). Indeed, LCs have been 
implicated in the induction of regulatory T-cells and are crucial 
for establishing tolerance to mild contact allergen sensitization 
by expanding regulatory T-cells while deleting allergen-specific 
CD8+ T-cell responses (61–63). Accordingly, transgenic over-
expression of RANKL by keratinocytes reduces CHS responses, 
and this was shown to be mediated by an enhanced capacity of 
LCs to expand CD4+CD25+ regulatory T-cells (64). These sup-
pressive functions of steady-state LCs were reported earlier in 
human skin, where LCs were shown to activate skin-resident 
regulatory T-cells (10). Interestingly, these studies demonstrated 
that the activation state of LCs determined their immunological 
response, as activated LCs induced effector T-cells and limited 
regulatory T-cell activation both in mice (63) and humans (10). 
In conclusion, by studying CHS responses to haptens, it became 
clear that LCs can contribute to contact allergen sensitization 
depending on the hapten dose and on the experimental mouse 
model that is used.
By making use of a transgenic mouse model expressing 
CD1a, a lipid-presenting protein normally not present in mice, 
it was shown that LCs that transgenically expressed CD1a 
showed a suppressed CHS to dinitrofluorobenzene. However, 
these CD1a+ LCs were able to induce Th17 responses to the topi-
cal application of inflammatory plant lipids (65). This indicates 
that the nature of the hapten can provoke antigen presentation 
by LCs that skews T-cell responses in a specific direction. 
Nevertheless, it remains unclear why in some patients toler-
ance is broken and contact dermatitis occurs, and how LCs are 
involved in this process. In conclusion, it is crucial to take into 
account the dose, nature, and application route of the hapten 
when drawing conclusions from mouse models of CHS. Also, 
the loss of LCs due to a severe inflammatory stimulus or injury 
will be replenished by circulating Gr-1hi monocytes, whereas the 
loss of LCs due to a less severe stimulus can be resolved by local 
proliferation of LCs (20). This implies again that the composi-
tion of the LCs pool and their contribution to CHS may vary 
between experimental models.
Allergic Sensitization to Protein Antigens
Like contact allergens, protein allergens from, e.g., mold, pollen, 
house dust mite (HDM), and cockroach can be present in high 
amounts at the skin surface. However, when studying allergic 
sensitization, it is important to note that haptens easily penetrate 
into the deeper skin layers and activate dermal DCs, whereas it 
is until now unclear whether protein allergens are able to do so 
without prior barrier disruption. Therefore, many experimental 
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models inflict epidermal barrier disruption prior to protein anti-
gen exposure, for instance by tape stripping or by using irritants 
such as acetone. These handlings will also activate keratinocytes 
and immune cells in the skin and induce mild inflammation (66). 
Consequently, epidermal barrier perturbation, prior to allergen 
exposure, influences the outcome of diverse experimental mod-
els used to study allergic responses and should be taken into 
consideration. Nakajima et al. reported that LCs are crucial for 
epicutaneous sensitization to ovalbumin (OVA) (67), whereas we 
recently demonstrated that dermal type 2 cDCs and not LCs are 
responsible for skin sensitization to HDM (68). We found that 
LC-depleted mice can be efficiently sensitized to HDM via the 
skin and HDM-loaded LCs are unable to transfer sensitization 
to naïve mice (68). The major discrepancy between these models 
lies in the fact that OVA is an inert protein that requires prior 
tape stripping, which enables penetration and functions as an 
adjuvant by activating keratinocytes and immune cells, whereas 
the HDM extract itself contains proteolytic active enzymes and 
contaminating endotoxins that can activate keratinocytes and 
immune cells to produce pro-allergic cytokines. The fact that 
these models induce keratinocyte activation in a different man-
ner could explain divergent roles for LCs during sensitization. 
Emerging evidence reveals an important interplay between 
epithelial cells and DCs during allergic sensitization, both in the 
lungs and in the skin (69). We previously showed that endotoxin-
induced toll-like receptor (TLR4) signaling on bronchial epithe-
lial cells is required for Th2 priming to HDM (70) via production 
of Th2-skewing cytokines (71). Likewise, activated keratinocytes 
can produce typical pro-allergic cytokines that skew DCs to 
prime Th2 cells, such as thymic stromal lymphopoietin (TSLP), 
IL-33, IL-1α, and GM-CSF (4). Interestingly, TSLP stimulates 
human LCs to induce pro-allergic T-cells (72). Of note, the pro-
allergic maturation effect of TSLP was restricted to epidermal 
LCs and does not occur in CD34+-derived LCs (73). However, 
LCs are dispensable for the TSLP-driven Th2 priming in a mouse 
model where TSLP overproduction is evoked by application of a 
vitamin D3 analog (74). Remarkably, we found that neither bar-
rier perturbation prior to sensitization nor proteolytic activity 
present in HDM is required for efficient epicutaneous sensitiza-
tion to HDM (68).
Although we did not find a crucial role for LCs during skin 
sensitization to HDM, we demonstrated that the lack of LCs 
results in increased production of type 2 cytokines by HDM-
restimulated T-cells in the lymph nodes (68). Our findings are in 
line with previous studies showing that LCs can exert regulatory 
functions (9, 10, 62) and thus might also be able to suppress Th2 
priming to HDM. Again, as in CHS, these contradictory findings 
indicate that multiple factors determine whether and how LCs 
contribute to epicutaneous sensitization. For instance, if allergens 
get in contact with the disrupted skin barrier of genetically pre-
disposed individuals, they may circumvent the potential suppres-
sive homeostatic function of LCs and gain direct access to dermal 
DCs. Also, in patients with a minimal degree of inflammation 
in the skin, LCs might be skewed toward a pro-allergic state. 
In conclusion, the exact role of LCs in epicutaneous sensitiza-
tion is yet to be elucidated, and recent findings point to a high 
functional redundancy between different skin DC subsets.
LCs iN ATOPiC DeRMATiTiS (AD)
Eczema or AD is a Th2-driven disease that often precedes aller-
gic or asthmatic responses in a progressive process termed the 
atopic march. Even though the role of LCs in sensitization to 
protein allergens is still under debate, LCs might also contribute 
to the effector phase of allergic reactions in the skin, causing 
symptoms of AD (Figure 2). However, reports from AD patients 
are limited and the exact role of LCs in this setting remains to 
be elucidated. In skin biopsies from AD patients, more LCs are 
present, although it is unclear whether these are skin-resident 
or monocyte-derived LCs (75). These authors show that TSLP 
causes proliferation of skin-resident LCs, while unaffecting the 
proliferation of a marginal wave of monocyte-derived LCs (75). 
Human LCs are in an activated state in AD lesions as demon-
strated by enhanced CD80 and CD86 expression (76), which was 
corroborated by the observation that murine LCs also express 
increased maturation markers in a mouse model of AD and this 
correlated with AD severity (77).
Human skin with defective epidermal barrier function, as is 
the case in patients with mutations in the filaggrin gene encod-
ing for a major structural protein in keratinocytes, predisposes 
to AD development (78). Interestingly, it was recently shown 
that in skin biopsies of patients harboring filaggrin-null muta-
tions, LCs are in a more activated state compared to control 
patients, irrespective of whether these patients suffered from 
AD (79). These authors demonstrate that filaggrin breakdown 
products, which act as natural moisturizing factors in the 
skin, reduce the maturation phenotype of ex vivo generated 
monocyte-derived DCs. Together, this indicates that filaggrin 
mutations can affect LC function (Figure 2), but whether this 
results in LC hyperactivation that instigates AD symptoms 
remains to be explored.
Another indication that LCs might exert an important role in 
the effector phase of AD is the observation that LCs from AD 
lesions display increased expression levels of the high-affinity 
immunoglobulin (Ig)E receptor (FcεRI) (80, 81). This receptor 
binds allergen-specific IgE molecules, thereby promoting antigen 
focusing to the cell surface and subsequent antigen uptake (82). 
Interestingly, in human CD34+-derived LCs, TLR2 ligation by 
Staphylococcus aureus products resulted in downregulation of 
FcεRI expression (83).
Recently, it was postulated that the AD-resolving effect of pho-
totherapy could be mediated by LCs. Ultraviolet (UV)B irradia-
tion generates photoproducts that activate the aryl hydrocarbon 
receptor (84), which in turn downregulates FcεRI in ex vivo 
generated, CD34+-derived LCs (85). Additionally, a recent report 
showed that activation of AhR by benzopyrene present in ciga-
rette smoke induced LC mobilization in association with reduced 
E-cadherin levels in keratinocytes (86). Moreover, AhR-deficient 
LCs showed an impaired maturation, which resulted in a reduced 
CHS to haptens (87). Both events indicate that benzopyrene could 
either directly or indirectly activate pro-inflammatory pathways 
in LCs that may worsen AD, but this remains to be investigated. 
AhR expression levels are also increased in AD skin (86), and 
this receptor was recently proposed to link air pollution to AD 
(88). Together, these reports imply that the nature of AhR ligand 
FiGURe 2 | Schematic representation of Langerhans cell (LC) functions in atopic dermatitis (AD). In skin of AD patients, a defective barrier can be due to mutations 
in the gene encoding for the structural protein filaggrin. During keratinocyte differentiation, the filaggrin monomer is degraded to the level of natural moisturizing 
factors, which can alter dendritic cell behavior. The defective epidermal barrier leads to the induction of LCs, which can enhance their proliferation rates and exhibit 
an enhanced activation state. Upon sensing environmental insults, an additional type 17 response is mounted, and LCs migrate to the lymph node to present 
antigen.
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could define a pro- or anti-inflammatory stimulus for LCs that 
may contribute to disease outcome.
Langerhans cells are important in raising cutaneous Th17 
responses to certain bacterial infections. Interestingly, HDM-
specific T-cells from AD patients were found to present either 
a Th2, Th17, or Th2/Th17 phenotype (89). Moreover, the 
percentage of Th17 cells and the level of circulating IL-17/IL-23 
cytokines in peripheral blood of AD patients correlate with dis-
ease severity (90, 91). How exactly this additional Th17 response 
arises in AD, a typical Th2-mediated disease, remains unclear. 
One possible explanation is that a defective barrier, induced by 
genetic defects or scratching, could facilitate microbial dysbiosis 
of the skin. Indeed, AD patients regularly suffer from concomi-
tant S. aureus colonization, which aggravates the disease (92). 
Kobayashi et al. demonstrated that mice that develop eczema-
tous skin with a disrupted epidermal barrier are more prone to 
develop S. aureus colonization and concomitant cutaneous Th17 
immune responses. This inflammatory phenotype was mediated 
by infiltrating γδ T-cells and Th17 cells and was abrogated when 
mice lacked LCs (93). Likewise, human LCs were shown to have a 
high capacity to induce IL-22 production by γδ T-cells, which in 
turn have potent clearing effects on S. aureus (94). In conclusion, 
LCs can exert different functions during AD depending on the 
stimuli they receive from the microenvironment. This explains 
why, despite many efforts, researchers have hitherto been unable 
to ascribe an unambiguous role for LCs in AD.
LCs iN PSORiASiS
Psoriasis is a chronic, inflammatory skin disorder manifested 
by the presence of silvery scaling on the affected regions 
and characterized by increased proliferation and abnormal 
differentiation of keratinocytes. In psoriatic skin, there is an 
accumulation of immune cells, of which DCs and T-cells are the 
most essential (95). The current knowledge on the role of LCs 
in human psoriatic patients is reviewed extensively in another 
review article in this research topic (5). In mice, a psoriasis-
like immune response in the skin can be mimicked by topical 
application of the TLR7 and -8 ligand imiquimod (IMQ), and 
the dermatitis induced in this experimental model depends on 
IL-23/Th17 signaling (96). LC-depleted mice show decreased 
IMQ-induced dermatitis and significantly reduced levels of 
IL-23, indicating that LCs are a major source of IL-23 in this 
model (97). In contrast, Wohn et al. reported that cDCs, and 
not LCs, are responsible for IL-23 production and subsequent 
dermatitis (98). These contradictory findings, both deduced by 
using the same Langerin-DTR mouse strain, might be due to 
the difference in topical IMQ application, namely on the ear 
versus the back skin. This could indicate that based on their 
location within the body, LCs might induce different tissue 
responses.
Mice that ectopically express the human lipid-presenting 
protein CD1a on LCs exhibit an aggravated psoriatic response 
on IMQ treatment, which could be reduced by administration of 
a CD1a-blocking antibody. Also in human patients, the inflam-
matory cytokine response typical for psoriasis was blocked by 
treatment with anti-CD1a antibodies (65). These observations 
exemplify the importance of lipid antigen presentation in the 
pathogenesis of psoriasis. Among the inflammatory mediators 
of psoriasis, TNF and IL-1β have been proven to be essential 
components of the cytokine storm that is typical in active flares 
of the disease (99). Recently, it was demonstrated that the main 
DCs responsible for the production of these pro-inflammatory 
cytokines are monocyte-derived DCs, including a population of 
LCs (100). These recent observations reemphasize the role of LCs 
in mounting the Th17 arm of the immune response that occurs 
in psoriatic skin. As neutralizing IL-17α is highly effective in the 
treatment of psoriasis (101), specific therapeutic targeting of LCs 
in the context of psoriasis might therefore represent an interest-
ing therapeutic avenue.
LC-ASSOCiATeD PATHOLOGieS
Langerhans cell histiocytosis is a disorder of unknown etiol-
ogy with varying clinical manifestations and disease severity, 
which is characterized by the infiltration of activated DCs in 
multifocal lesions (102, 103). A common clinical feature of 
LC histiocytosis is a skin eruption soon after birth, which may 
resolve spontaneously or spread to other regions of the body. 
Although Birbeck granules have been observed in cells within 
these lesions, the LC origin of these histiocytoses has not been 
formally proven. LC histiocytoses encompass many subtypes 
with a wide range of clinical manifestations, which are charac-
terized by inflammation and hyperproliferation of leukocytes 
and can involve skin, bone, lung, bone marrow, central nervous 
system, and lymph nodes (104). Recent reports have demon-
strated that in two thirds of patients activating mutations in the 
RAF/MEK/ERK pathway occur within LC histiocytic lesions 
(105, 106). Current therapeutic treatments encompass MEK or 
BRAF inhibitors or a combination of both, as recently reviewed 
by Haroche et al. (104). The current mouse model developed to 
study LC histiocytosis, by transgenic expression of the simian 
virus 40-derived oncogenes under control of the CD11c pro-
moter, not only mimics certain features of the disease but also 
exhibits hallmarks of LC sarcoma (107). Therefore, this animal 
model might not represent the best tool to study the etiology of 
LC histiocytosis.
Langerhans cell sarcoma is a rare neoplastic LC disorder that 
can form de novo or can arise from LC histiocytosis (108). So far, 
no recurrent chromosomal modifications have been identified 
in both disorders, but further studies to correctly classify and 
potentially stratify these diseases are necessary.
LCs iN CANCeR
Non-melanoma skin tumors include basal cell carcinomas and 
squamous cell carcinomas (SCCs), which typically exhibit a 
severely reduced LC presence in the peritumoral and tumoral 
regions (109). As DCs are able to elicit potent antitumor immune 
responses, it is generally excepted that they play a crucial role 
in cancer immune surveillance. However, DCs can exhibit 
functional alterations in certain tumor types and become less 
potent in T-cell stimulation and production of interferons, 
enabling escape from immune surveillance (110, 111). Various 
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reports point to a crucial role for LCs in mediating malignant 
progression in the skin. In human SCCs, suppression of DC 
functionality was observed, while LCs isolated from SCCs have 
been shown to be potent type 1 immune stimulators in  vitro 
(112). Interestingly, LCs migrate abnormally from SCC skin 
and have reduced T cell priming abilities within the lymph node 
(113). Many cytokines that are known to mediate LC migration 
out of the dermis, such as TSLP, IL-1, and TNF, have been impli-
cated in cutaneous cancer models (114–116). Aberrations in 
the epidermal permeability barrier prime the secretion of these 
pro-inflammatory cytokines, resulting in altered cancer sus-
ceptibility (117). However, it remains to be established whether 
in these conditions, enhanced LC migration is an underlying 
cause of skin tumorigenesis. Given the recent discovery of 
Langerin-expressing DCs beyond LCs, it is plausible that many 
of the tumor biology effects that were attributed to LCs are in 
fact due to other Langerin+ cells in the skin, and therefore, these 
observations need to be revisited. Human LCs have been shown 
to be more efficient activators of naïve CD8+ T-cells than dermal 
DCs, which might have important implications for antitumor 
responses (118). In the widely established two-stage DMBA/TPA 
model of chemical skin carcinogenesis, Langerin-deficient mice 
are fully protected from papillomagenesis and subsequent SCC 
formation (119). These authors demonstrate that Langerin+ cells 
can enhance DMBA-induced DNA damage, although in light of 
recent findings, it remains to be established whether the LCs are 
the main Langerin+ DCs that are capable of metabolizing DMBA. 
Indeed, various reports now show that the DMBA-metabolizing 
activity of LCs is dispensable for inflicting H-Ras mutations in 
keratinocytes (120, 121).
Treatment with ionizing radiation is frequently used as a 
localized tumoricidal therapy in cancer patients; however, recent 
data point to the induction of additional antitumor immune 
responses by radiotherapy, such as infiltration by regulatory 
T-cells within the tumor and activation of APCs (122, 123). 
LCs are remarkably radio-resistant and are highly potent in 
rapidly repairing the inflicted DNA damage, which was shown 
to be mediated by CDKN1A (cyclin-dependent kinase inhibi-
tor) (124). Repetitive damage by UVB irradiation predisposes to 
melanoma formation and given the staggering success of immu-
notherapeutic interventions in melanoma patients, it is pivotal 
to understand the immune cell dynamics within the melanoma 
microenvironment. Based on the coexpression of S100 (125) and 
CD1, a reduction of LCs in the epidermis overlying melanoma 
has been reported (126). This reduced number of LCs might rep-
resent an early event after UVB photodamage, as LC migration 
to the lymph nodes occurs after UVB irradiation (19). A recent 
report demonstrates that keratinocytes reduce αvβ6 and αvβ8 
integrin expression after UVB damage, resulting in downregula-
tion of TGF-β signaling in LCs and subsequent migration of LCs 
out of the epidermis (127).
During malignant conversion of tumors, epithelial cells can 
lose their cell polarity and adhesive properties in order to become 
more invasive and mesenchymal. LCs might also play a role in 
these epithelial–mesenchymal transitions (EMT) in cutaneous 
cancers, as many molecules that are involved in mediating LC 
migration in and out of the epidermis are known to play a role 
in various stages of the EMT process (128). TGF-β as a major 
transcription factor involved in LC behavior also acts as a mas-
ter regulator of EMT processes in skin cancers (129). BMP7 is 
important to maintain LCs in the epidermis in a rested state. In 
cancers, BMP7 plays a similar role as it promotes reversed EMT, 
namely mesenchymal to epithelial transition, clearly acting as a 
homing signal to epithelia (36, 130). One of the signature events 
that characterize EMT is the loss of E-cadherin expression, 
which as mentioned above is a prerequisite for LC migration out 
of the epidermis (2). Interestingly, as mentioned above, secreted 
E-cadherin induces β-catenin stabilization, an event that occurs 
in various cutaneous tumors and leads to tolerogenicity in DCs 
(22, 23). Whether tolerogenic LCs contribute to tumorigenesis 
in Wnt-activated cutaneous tumors, remains to be investigated. 
The receptor tyrosine kinase Met is expressed on all DCs and was 
originally characterized as an oncogene. Met signaling is crucial 
for the migration of LCs from the skin to the lymph nodes as LCs 
in mice that lack Met do not reach the skin-draining lymph node 
in inflammatory conditions (131). Interestingly, Met signaling 
mediates the enzymatic activity of MMP-2 and -9, the aforemen-
tioned proteases that are crucial for LCs to breach the basement 
membrane when emigrating out of the epidermis (132).
DiSCUSSiON AND OUTSTANDiNG 
QUeSTiONS
Despite the fact that LCs were first described over a century 
ago, there are still many outstanding questions regarding their 
biological functions and redundancies in skin homeostasis and 
pathology. The identification of dermal subsets of Langerin+ DCs, 
independent of epidermal LCs that are in transit to skin-draining 
lymph nodes, questioned the validity of the LC paradigm and 
therefore the biological function of LCs in different pathological 
contexts needs to be revisited. In order to better understand LC 
biology, more extensive studies on human LC biology are needed. 
Highly elegant studies have recently indicated the complexity of 
human DCs, unveiling the existence of multiple pre-DC precur-
sors that have distinct functional properties (133). There is also 
a need for mouse models enabling specific targeting of LCs, 
without affecting other DC subsets. The use of mouse models 
that enable inducible targeting of LCs might be beneficial over 
constitutive LC deletion, as it might well be that life-long absence 
of specific leukocyte subsets affects normal skin development 
and homeostasis. A better understanding of the relative contri-
butions of skin-resident DC subtypes in mounting the plethora 
of tissue responses that occur in the skin upon various insults 
and trauma will improve the development of DC vaccines and 
other targeted therapies.
The skin hosts trillions of microorganisms that have been 
proven crucial for tissue homeostasis and immunity. It was 
shown that mice lacking functional LCs mount normal T-cell 
responses relative to control littermates following infection with 
the skin commensal Staphylococcus epidermidis (134). However, 
LCs are crucial in raising a humoral protective response after 
topical application of the S. aureus-derived exfoliative toxin A 
(135). These data point to the potential use of Langerin-based 
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therapies in protection from infection, although microbial 
restriction by LCs seems to be based on receptor usage and hence 
can only be deployed against certain microbes (136). Whether 
LCs are key players in establishing a healthy skin microbiome 
remains to be investigated. It would also be worthwhile to 
investigate whether LCs develop normally in the absence of 
commensal microbes as would be the case in germ-free animals. 
It is clear that altering LC functions could be an interesting 
therapeutic avenue in various disease contexts. Glycans are cru-
cial determinants in the binding of C-type lectin receptors, such 
as Langerin, to their ligands and can be modified in order to 
alter immune modulation on many levels, from immune recog-
nition of pathogens to regulating adaptive immune responses, 
which could be exploited to modulate immune surveillance, as 
reviewed elsewhere (137, 138). In the current era of single-cell 
technologies, it is possible to question whether multiple subsets 
exist within the LC population and how these could affect tis-
sue immune responses. Such studies might shed light on the 
controversial roles that have been attributed to LCs in infection 
and cancer and would pave the way for therapeutic targeting of 
this unique cell-type.
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